Individualised treatment of postherpetic neuralgia

+Summer Hiatus

In print

Practice + Clinical update

Individualised treatment of postherpetic neuralgia

By Vanessa Brown

Sunday 22 December 2024, 12:30 PM

[Image: Fisle, CC BY-SA 3.0]

We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!

This article was first published online on 10 April.

This article examines the options available for management of pain associated with postherpetic neuralgia

This Practice article has been endorsed by the RNZCGP and has been approved for up to 0.25 credits for continuing professional development purposes (1, Educate small, BACK panel - grey

Pain

Neurology

Infectious Disease

Medicines and Therapies

Older People

Summer Hiatus archive

How to Treat

+How to treat

Polypharmacy

For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews

Wednesday 28 May 2025, 12:50 AM